EWTX vs SRPT: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

EWTX is the larger of the two ($4.41B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 0.40). SRPT is the smaller challenger ($1.47B), expected to make money next year (9.12x forward earnings): more room to run, but more to prove. If the story you believe is EWTX's (EDG-7500 in hypertrophic cardiomyopathy), EWTX is the more direct way to own it; if it is SRPT's (Elevidys franchise durability), SRPT is.

EWTX vs SRPT: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricEWTXSRPTWhat it tells you
Market cap$4.41B$1.47BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-20.539.12Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E4.80685.00Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.400.45Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range71% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.700.96How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how EWTX and SRPT affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EWTX and SRPT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EWTX and SRPT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Edgewise Therapeutics (EWTX) do?

Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for serious cardiac conditions. Until mid-2026 its lead candidate was sevasemten (formerly EDG-5506), a skeletal myosin inhibitor for Becker and Duchenne muscular dystrophy. In a deal that closed in July 2026, Edgewise sold sevasemten and its muscular dystrophy business to Servier, receiving about $1.4 billion in cash at closing (Servier has described a $1.55 billion upfront), with up to about $1.1 billion more in potential regulatory and commercial milestones reported alongside it. On November 4, 2026 Servier said the 18-month GRAND CANYON study of sevasemten in Becker did not meet its primary endpoint, the North Star Ambulatory Assessment, or its secondary endpoints, while safety remained favourable. Edgewise had already been paid, so the failure falls on Servier, though it makes the sevasemten milestones much less likely to be earned.

Full EWTX guide

What does Sarepta Therapeutics (SRPT) do?

Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease. Its portfolio has two pillars: Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for DMD delivered with the AAVrh74 viral vector, and an older RNA-based exon-skipping franchise (Exondys 51, Vyondys 53, Amondys 45) that treats subsets of patients by helping cells skip faulty sections of the dystrophin gene. Roche holds ex-US commercialization rights to Elevidys, which produces meaningful licensing and royalty revenue for Sarepta. Earlier in 2026 the company reiterated net product revenue guidance of roughly $1.2 billion to $1.4 billion for the year.

Full SRPT guide

EWTX vs SRPT: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • EWTX drivers: EDG-7500 in hypertrophic cardiomyopathy; The Servier sale and what it left behind.
  • SRPT drivers: Elevidys franchise durability; Cash-generative base RNA business.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value now depends almost entirely on two cardiac programs, so a disappointing EDG-7500 Phase 3 or an FDA setback would remove most of the expected value above cash. For SRPT, the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage.

EWTX or SRPT: which should you pick?

With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate EWTX from SRPT. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EWTX and SRPT guides.

EWTX vs SRPT: the full fundamentals

EWTX. Edgewise generates no product revenue, so traditional valuation multiples do not apply, and the trailing P/E near 5 reflects only the one-time gain on the Servier sale. Subtracting about $1.74 billion of cash from the roughly $4.4 billion market value leaves an enterprise value near $2.7 billion for EDG-7500, EDG-15400 and the platform. Analysts average a $55.42 target across 12 analysts with a strong buy rating, and Wedbush trimmed its target to $51 from $53 in November 2026 while keeping an outperform rating.

SRPT. SRPT closes near $13.74 on November 20, 2026, giving a market cap near $1.5 billion, roughly 87 percent below its early-2025 value of over $11 billion and just under book value (about 0.96x). At about 0.75x trailing sales and 9x forward earnings the stock looks cheap on paper, but consensus expects revenue to fall to about $1.38 billion in 2027 and EPS to drop to about $1.50 from about $3.92 in 2026, and the trailing year shows a net loss of about $115 million. Valuation reflects deep uncertainty about gene-therapy adoption and new Duchenne competition rather than a going-concern question about the base RNA business.

Headline figures (approximate, November 2026): EWTX shows product revenue ~$0 (pre-commercial), cash & investments (september 30, 2026) ~$1.74B after the Servier sale; debt ~$3M, q3 2026 net income ~$1.17B ($9.65 diluted EPS), from a ~$1.35B one-time gain on the sale less ~$155M tax, q3 2026 operating expenses R&D ~$31.6M (vs ~$37.5M), G&A ~$14.6M (vs ~$9.4M); SRPT shows market cap ~$1.5B, revenue (ttm) ~$1.96B, q3 2026 revenue growth ~-4.5% YoY (~$381M), q3 2026 adjusted eps vs estimate $0.13 vs ~$0.36.

The bottom line: EWTX vs SRPT

EWTX and SRPT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined EWTX and SRPT exposure against your real portfolio. It is not an investment adviser.

Wondering how EWTX or SRPT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Edgewise Therapeutics

Ask Walnut's AI anything about EWTX and see how it fits what you own.

FAQ

What is the difference between EWTX and SRPT?

+

Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for serious cardiac conditions. Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is EWTX or SRPT the better stock?

+

Neither is universally better. EWTX is the larger incumbent; SRPT is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, EWTX or SRPT?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both EWTX and SRPT?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of EWTX vs SRPT?

+

EWTX: As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value now depends almost entirely on two cardiac programs, so a disappointing EDG-7500 Phase 3 or an FDA setback would remove most of the expected value above cash. The company sold its most advanced asset, which removed one shot on goal along with its risk, and the GRAND CANYON failure means the sevasemten milestones are unlikely to add much. The HCM field is crowded with better-capitalized rivals, including Bristol Myers Squibb's approved Camzyos and Cytokinetics' aficamten, so EDG-7500 must show a genuinely differentiated safety and efficacy profile to matter commercially. HFpEF has a long record of failed trials, and EDG-15400 is still at an early stage. Trailing earnings figures are distorted by the one-time gain on the Servier sale, and analysts expect losses of about $1.86 per share in 2027, so the trailing P/E near 5 is not a measure of value. G&A costs rose about 55% year over year in the third quarter. The shares have fallen about 9% over three months even after the sale, and they can move sharply on trial news, competitor data or decisions about how the cash is deployed. SRPT: The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences: Dyne's exon 51 program is under FDA review, RBC called REGENXBIO's RGX-202 'approvable' in November 2026, and PepGen's rare-disease data that month put more pressure on DMD and DM1 incumbents. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated. Revenue is shrinking from its peak: Q3 2026 revenue fell about 4.5% year over year, Q3 adjusted EPS of $0.13 missed a $0.36 consensus, and analysts see 2027 revenue roughly 26% below 2026, so the stock's low multiples (about 0.75x sales, about 9x forward earnings) sit on a declining base. The share price is down about 36% year to date as of November 20, 2026, and analysts on average rate it a hold.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EWTX or SRPT; figures are approximate and dated (as of November 2026). Verify current data before investing.